Details

Autor(en) / Beteiligte

• Knapp, Stephen T
• Revette, Anna
• Underhill-Blazey, Meghan
• Stopfer, Jill E
• Ukaegbu, Chinedu I
• Poulin, Cole
• Parenteau, Madison
• Syngal, Sapna
• Bae, Eunchan
• Bickmore, Timothy
• Hampel, Heather
• Idos, Gregory E
• Parmigiani, Giovanni
• Yurgelun, Matthew B
• Braun, Danielle

Titel

MyLynch: A Patient-Facing Clinical Decision Support Tool for Genetically-Guided Personalized Medicine in Lynch Syndrome

Ist Teil von

• Cancers, 2023-01, Vol.15 (2), p.391

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Lynch syndrome (LS) is a hereditary cancer susceptibility condition associated with varying cancer risks depending on which of the five causative genes harbors a pathogenic variant; however, lifestyle and medical interventions provide options to lower those risks. We developed MyLynch, a patient-facing clinical decision support (CDS) web application that applies genetically-guided personalized medicine (GPM) for individuals with LS. The tool was developed in R Shiny through a patient-focused iterative design process. The knowledge base used to estimate patient-specific risk leveraged a rigorously curated literature review. MyLynch informs LS patients of their personal cancer risks, educates patients on relevant interventions, and provides patients with adjusted risk estimates, depending on the interventions they choose to pursue. MyLynch can improve risk communication between patients and providers while also encouraging communication among relatives with the goal of increasing cascade testing. As genetic panel testing becomes more widely available, GPM will play an increasingly important role in patient care, and CDS tools offer patients and providers tailored information to inform decision-making. MyLynch provides personalized cancer risk estimates and interventions to lower these risks for patients with LS.